JP2024530315A5 - - Google Patents

Info

Publication number
JP2024530315A5
JP2024530315A5 JP2024513277A JP2024513277A JP2024530315A5 JP 2024530315 A5 JP2024530315 A5 JP 2024530315A5 JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024530315 A5 JP2024530315 A5 JP 2024530315A5
Authority
JP
Japan
Prior art keywords
ray powder
crystalline form
powder diffraction
diffraction pattern
morphology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530315A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/116084 external-priority patent/WO2023030363A1/en
Publication of JP2024530315A publication Critical patent/JP2024530315A/ja
Publication of JP2024530315A5 publication Critical patent/JP2024530315A5/ja
Pending legal-status Critical Current

Links

JP2024513277A 2021-08-31 2022-08-31 Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法 Pending JP2024530315A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021115718 2021-08-31
CNPCT/CN2021/115718 2021-08-31
PCT/CN2022/116084 WO2023030363A1 (en) 2021-08-31 2022-08-31 Solid forms of bcl-2 inhibitors, method of preparation, and use thereof

Publications (2)

Publication Number Publication Date
JP2024530315A JP2024530315A (ja) 2024-08-16
JP2024530315A5 true JP2024530315A5 (cg-RX-API-DMAC7.html) 2025-09-03

Family

ID=85410866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513277A Pending JP2024530315A (ja) 2021-08-31 2022-08-31 Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法

Country Status (10)

Country Link
US (1) US20240317743A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396180A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024530315A (cg-RX-API-DMAC7.html)
KR (1) KR20240054327A (cg-RX-API-DMAC7.html)
CN (1) CN118215660A (cg-RX-API-DMAC7.html)
AU (1) AU2022336557A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230314A1 (cg-RX-API-DMAC7.html)
IL (1) IL311106A (cg-RX-API-DMAC7.html)
MX (1) MX2024002465A (cg-RX-API-DMAC7.html)
WO (1) WO2023030363A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116969937B (zh) 2020-04-15 2026-03-24 百济神州(苏州)生物科技有限公司 Bcl-2抑制剂
TW202604488A (zh) 2024-06-26 2026-02-01 瑞士商百濟神州I有限責任公司 包含索托克拉固體分散體之醫藥調配物及其製備方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2546294T7 (es) * 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
KR101762724B1 (ko) * 2011-01-25 2017-07-28 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
CN112437772B (zh) * 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Similar Documents

Publication Publication Date Title
JP2020536960A5 (cg-RX-API-DMAC7.html)
ES2527768T5 (es) Sales cristalinas de sitagliptina
CN101068793B (zh) Hiv整合酶抑制剂的钾盐
JP4142621B2 (ja) 純結晶形態の5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニルおよび合成方法
RS55353B2 (sr) Tenofovir alafenamid hemifumarat
TW202214601A (zh) Apol1抑制劑之固體形式及其使用方法
JP2022512824A5 (cg-RX-API-DMAC7.html)
JP2025508071A5 (cg-RX-API-DMAC7.html)
TWI377205B (en) Isoxazoline derivative and novel process for its preparation
IL297041A (en) Inhibitors of human immunodeficiency virus replication
TW201617315A (zh) 異吲哚啉酮衍生物
WO2024206647A1 (en) Polymorphic forms and salts of a glp-1r agonist
JP2025102940A5 (cg-RX-API-DMAC7.html)
TW201625549A (zh) 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途
TWI808069B (zh) [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式
TW202019406A (zh) 經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法
WO2019119832A1 (zh) 用于代谢性疾病治疗的化合物及其制备方法和应用
JP2005529084A (ja) 結晶性パレコキシブナトリウム
JP2024001040A5 (cg-RX-API-DMAC7.html)
CN111592485A (zh) 盐酸替罗非班及其游离碱的晶型及其制备方法
JP7448541B2 (ja) 選択的エストロゲン受容体分解剤の新規な塩
CN118401525A (zh) 吡唑并[3,4-d]嘧啶化合物的固体形式
JP2004530706A (ja) 純粋な結晶形態にある5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニル及び合成方法
CA3244893A1 (en) PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4-YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC AND ITS CRYSTALLINE FORMS FOR USE AS A PHARMACEUTICALLY ACTIVE COMPOUND
JP2024520897A5 (cg-RX-API-DMAC7.html)